Table 2.
Adverse events and immune-related adverse events in all patients with advanced non-small cell lung cancer.
| Category | Number of patients (%) | ||
|---|---|---|---|
| Total | Grade 1-2 | Grade 3-5 | |
| Any AEs | 65 (92.9) | 55 (78.6) | 39 (55.7) |
| Any irAEs | 42 (60.0) | 31 (44.3) | 12 (17.1) |
| Pneumonitis | 10 (14.3) | 6 (8.6) | 4 (5.7) |
| Rash | 20 (28.7) | 18 (25.7) | 2 (2.9) |
| Hypothyroidism/Hyperthyroidism | 9 (12.9) | 9 (12.9) | 0 (0) |
| Adrenal insufficiency | 3 (4.3) | 2 (2.9) | 1 (1.4) |
| Hypophysitis | 1 (1.4) | 0 (0) | 1 (1.4) |
| Hepatitis | 2 (2.9) | 1 (1.4) | 1 (1.4) |
| Nephritis | 1 (1.4) | 0 (0) | 1 (1.4) |
| Ocular inflammatory toxicity | 1 (1.4) | 0 (0) | 1 (1.4) |
| Pancreatitis | 1 (1.4) | 1 (1.4) | 0 (0) |
| Colitis | 1 (1.4) | 0 (0) | 1 (1.4) |
| Infusion reaction | 1 (1.4) | 1 (1.4) | 0 (0) |
AE, adverse event; irAE, immune-related adverse event.